HROW · Harrow, Inc.

Current Thesis

Harrow is a commercial-stage ophthalmology pharma whose stock now trades almost entirely on one question: does the second-half revenue ramp management is promising actually show up. Q1 2026 (reported 2026-05-12) printed $44.2M revenue against ~$52.6M consensus a 16% miss that knocked the shares down ~25.9% to a mid-May low near $34. The company pinned the gap on a one-time ~$8M VEVYE gross-to-net adjustment rather than softening demand, and reaffirmed full-year guidance of $350–365M revenue and $80–100M adjusted EBITDA, with Q2 guided to $71–81M. That Q2 figure implies a 60–80% sequential jump off Q1 the number that validates or breaks the whole guide. June's bounce back to ~$41, the VERKAZIA relaunch (2026-06-10), and a spike in retail chatter front-run a print that does not land until August. This is a sentiment-led recovery running ahead of an unconfirmed catalyst.

Bull Case

• Demand accelerated even as reported revenue missed. VEVYE set record prescriptions in Q1 2026, surpassed XIIDRA on monthly TRx, and reached ~14% dry-eye market share; Tier-1 accounts grew scripts ~170% sequentially, with NRx +25% / TRx +11% QoQ (Q1 call, 2026-05-12). The headline miss traced to an $8M gross-to-net true-up while underlying scripts grew.
• Portfolio momentum is broad. IHEEZO unit demand rose +18% YoY and TRIESENCE +136% YoY in Q1 2026 multiple products contributing to the ramp, broadening the story beyond VEVYE.
• Reaffirmed guide implies a steep H2 inflection. FY2026 revenue $350–365M and adjusted EBITDA $80–100M, with VEVYE alone guided above $100M annually (reaffirmed 2026-05-12). Clearing the $71–81M Q2 bar re-rates a name the Street still rates Strong Buy with targets clustered $59–76 (Lake Street raised to $70 from $42; H.C. Wainwright $60).
• Pipeline cadence intact. VERKAZIA relaunched 2026-06-10 CEO Mark Baum's second of three priority products from the Letter to Stockholders making a third launch the next discrete headline.

Bear Case

• Q1 was a real miss and the loss is widening. Net loss widened to $27.6M (from $17.8M YoY), EPS -$0.74, and adjusted EBITDA was -$12.7M in Q1 2026. The company is still burning cash going into the ramp it must deliver.
• The Q2 guide is the trap. A $71–81M Q2 off a $44.2M Q1 is a figure the company has to hit; anything near the low end or below resets the FY guide and the multiple. It is a show-me print roughly seven weeks out.
• June strength is sentiment-driven. William Blair characterized the VERKAZIA relaunch as not a major top-line driver. The bounce off $34, a surge in retail chatter, and an RSI in the low-70s read as froth running ahead of the catalyst.
• Leverage. Harrow carries meaningful senior-note debt against negative trailing adjusted EBITDA a rate- and execution-sensitive balance sheet that amplifies any guide reset.

Setup & Price Structure

The chart is a recovery, not a breakout. After the 2026-05-12 Q1 print, HROW fell ~25.9% and bottomed near $33.99 in mid-May, then climbed back to roughly $41 by mid-June. The VERKAZIA relaunch added +7.3% on 2026-06-10. Resistance sits at the pre-earnings gap shelf in the mid-$40s; reclaiming and holding that zone would signal the tape is starting to price the H2 ramp. The ~$34 reaction low is the line in the sand losing it says the bounce failed and the guide credibility is cracking. Retail-chatter velocity plus a low-70s RSI mark the move as extended near term; a name this far above its mid-May base, into a binary print still weeks away, is not a clean momentum entry. Better-defined risk comes on a pullback that holds above $34, or on the August print itself.

Catalyst Calendar (next 30 days)

• Monthly VEVYE / IHEEZO script trends (rolling, ~weekly-to-monthly): third-party TRx/NRx data is the highest-frequency tell on whether the Q2 ramp is materializing; any rollover before August is an early warning.
• Third priority-product launch (~unscheduled, est. summer 2026): management flagged three priority products; with VERKAZIA (2026-06-10) as #2, a #3 announcement is the next likely discrete headline inside the window.
• No earnings inside the window. Q2 2026 results the binary that validates the $71–81M guide are expected early-to-mid August 2026, outside 30 days. Treat any pre-print positioning as catalyst risk; the three trading days ahead of the report carry binary gap risk.

What Would Change Our Mind

The thesis strengthens if monthly VEVYE TRx keeps setting records into July and HROW reclaims the mid-$40s pre-earnings shelf, which would mean the market is discounting a clean Q2 beat. It breaks on a weekly close back below the mid-May low near $34 (the recovery fails and guide credibility erodes), or when the print lands in August Q2 revenue at or below the $71M low end, forcing a full FY-guide reset. A second consecutive gross-to-net or coverage-related revenue surprise would confirm the Q1 miss was structural rather than the one-time item management described.

Correlation Notes

HROW trades as an idiosyncratic specialty-pharma special situation; index beta is secondary to VEVYE script data and guidance credibility. Residual sensitivity runs through small-cap biotech risk appetite (XBI) and rates, given the debt load. Dry-eye competitive read-through links it to XIIDRA (Bausch + Lomb) share trends and peers such as Tarsus (TARS) and Aldeyra (ALDX); a competitor share-gain headline is a direct thesis risk. Effectively zero correlation to the mega-cap AI complex this is a clinical/commercial-execution name driven by its own print.